Pharmafile Logo

SpingWorks

- PMLiVE

Pfizer files third-gen ALK inhibitor for lung cancer

The US FDA is set to make a decision on lorlatinib later this year

- PMLiVE

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

Findings demonstrated a 71% reduction in cancer spreading and death

- PMLiVE

Pfizer and IBM’s tech-enabled ‘Parkinson’s house’

Pharma firm looks to technology to help it unlock the doors to breakthrough treatments

- PMLiVE

Pfizer drops neuroscience R&D, cutting 300 jobs

The new direction will see the termination of early-stage Parkinson’s and Alzheimer’s candidates

- PMLiVE

Pfizer buys into Sangamo’s motor neuron disease gene therapy

The pharma giant will pay $12m upfront and $150m in potential milestones

National Institute for Health and Care Excellence NICE logo

NICE to look again at Pfizer’s Besponsa after appeal

The blood cancer medicine was originally turned down on cost-effectiveness grounds

- PMLiVE

Novartis bags new breakthrough status for Kisqali in breast cancer

The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved

- PMLiVE

FDA’s year-end approvals take annual tally to 46

Rhopressa and Steglatro were among the final medicines licensed last year

- PMLiVE

Adopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Pfizer names Albert Bourla as COO

John Young and Angela Hwang also take up new positions at the pharma firm

Perspective on biotech leaders

In the latest issue of Perspective magazine, seven industry trailblazers reveal the trends, challenges and opportunities they anticipate in the biotech sector, from empowering patients to deciphering big data.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links